Navignostics utilizes spatial single-cell proteomics and multiplex protein imaging to analyze tumor samples, enabling precise identification of optimal therapies for individual cancer patients. This approach enhances personalized diagnostics and accelerates drug development by providing critical insights into tumor characteristics and drug mechanisms for clinicians and pharmaceutical partners.
Funding
$8.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment strategies often lack the precision needed to identify the most effective therapy for individual patients, leading to suboptimal outcomes and increased healthcare costs. Existing diagnostic tests may not reliably predict patient response to treatments like immunotherapies, resulting in many patients receiving treatments that ultimately prove ineffective. This challenge underscores the need for more comprehensive and personalized approaches to cancer diagnostics and treatment selection.
Solution
Navignostics addresses this issue by leveraging spatial single-cell proteomics and multiplex protein imaging to analyze tumor samples, enabling a highly detailed characterization of the tumor microenvironment. Their approach combines highly multiplex protein imaging with advanced data analytics for spatial single-cell proteomics, validated through translational and clinical research. By identifying the unique characteristics of each tumor, Navignostics helps clinicians select the optimal therapy for individual cancer patients and supports pharmaceutical companies in accelerating drug development. The company's services provide critical insights into drug mechanisms and tumor features, enhancing personalized diagnostics and improving patient outcomes. Navignostics' technology allows for in-depth cell phenotyping and characterization of cell-cell interactions within the tumor microenvironment, providing a comprehensive understanding of potential treatment responses.
Target Audience
Navignostics serves clinicians seeking to identify optimal therapies for their cancer patients, as well as pharmaceutical companies aiming to accelerate cancer drug development and identify biomarkers.
Features
- Spatial single-cell proteomics for advanced tumor sample analysis
- Highly multiplex protein imaging to visualize and quantify protein expression
- Advanced data analytics to identify predictive patterns and treatment responses
- In-depth characterization of the tumor microenvironment
- _In situ_ cell phenotyping to classify and quantify different cell types
- Characterization of cell-cell interactions to understand tumor dynamics
- Support for clinical trials by identifying patient groups most likely to benefit from novel treatments
- Rapid data acquisition and reporting, with demonstrated ability to go from samples to data reporting in under 72 hours